Klaudia Farkas
Klaudia Farkas
Verified email at
Cited by
Cited by
Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort
KB Gecse, BD Lovász, K Farkas, J Banai, L Bene, B Gasztonyi, ...
Journal of Crohn's and Colitis 10 (2), 133-140, 2016
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in …
LS Kiss, T Szamosi, T Molnar, P Miheller, L Lakatos, A Vincze, K Palatka, ...
Alimentary pharmacology & therapeutics 34 (8), 911-922, 2011
Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis–experiences from a single center
K Farkas, M Rutka, A Bálint, F Nagy, R Bor, Á Milassin, Z Szepes, ...
Expert opinion on biological therapy 15 (9), 1257-1262, 2015
Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis
K Farkas, M Rutka, PA Golovics, Z Végh, BD Lovász, T Nyári, KB Gecse, ...
Journal of Crohn's and Colitis 10 (11), 1273-1278, 2016
Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy
T Molnár, PL Lakatos, K Farkas, F Nagy, Z Szepes, P Miheller, G Horváth, ...
Alimentary pharmacology & therapeutics 37 (2), 225-233, 2013
Fecal MMP-9: a new noninvasive differential diagnostic and activity marker in ulcerative colitis
A Annaházi, T Molnár, K Farkas, A Rosztóczy, F Izbéki, K Gecse, O Inczefi, ...
Inflammatory bowel diseases 19 (2), 316-320, 2013
Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease
PL Lakatos, LS Kiss, K Palatka, I Altorjay, P Antal-Szalmas, E Palyu, ...
Inflammatory bowel diseases 17 (3), 767-777, 2011
Pregnancy outcome in patients with inflammatory bowel disease according to the activity of the disease and the medical treatment: a case–control study
T Molnár, K Farkas, F Nagy, PL Lakatos, P Miheller, T Nyári, G Horváth, ...
Scandinavian journal of gastroenterology 45 (11), 1302-1306, 2010
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy
JF Rahier, P Papay, J Salleron, S Sebastian, M Marzo, L Peyrin-Biroulet, ...
Gut 60 (4), 456-462, 2011
Preserved Na+/H+ exchanger isoform 3 expression and localization, but decreased NHE3 function indicate regulatory sodium transport defect in ulcerative colitis
S Yeruva, K Farkas, J Hubricht, K Rode, B Riederer, O Bachmann, ...
Inflammatory bowel diseases 16 (7), 1149-1161, 2010
Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics
MD Michael, A Bálint, BD Lovász, L Gulácsi, B Strbák, PA Golovics, ...
The European Journal of Health Economics 15 (1), 121-128, 2014
New therapeutic targets in ulcerative colitis: the importance of ion transporters in the human colon
K Farkas, S Yeruva, Z Rakonczay Jr, L Ludolph, T Molnár, F Nagy, ...
Inflammatory bowel diseases 17 (4), 884-898, 2011
Inhibition of cholesterol atherosclerosis by immunisation with beta-lipoprotein
S Gero, J Gergely, L Jakab, J Szekely, S Virag, K Farkas, A Czuppon
The Lancet 274 (7088), 6-7, 1959
Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy
K Farkas, PL Lakatos, F Nagy, Z Szepes, P Miheller, M Papp, K Palatka, ...
Scandinavian Journal of Gastroenterology 48 (12), 1394-1398, 2013
Do not forget the stool examination!—cutaneous and gastrointestinal manifestations of Blastocystis sp. infection
A Bálint, I Dóczi, L Bereczki, R Gyulai, M Szűcs, K Farkas, E Urbán, ...
Parasitology research 113 (4), 1585-1590, 2014
Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort
L Gonczi, KB Gecse, Z Vegh, Z Kurti, M Rutka, K Farkas, PA Golovics, ...
Inflammatory bowel diseases 23 (11), 1908-1915, 2017
Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells
LG Puskás, LZ Fehér, C Vizler, F Ayaydin, E Rásó, E Molnár, I Magyary, ...
Lipids in health and disease 9 (1), 1-9, 2010
Response to first intravenous steroid therapy determines the subsequent risk of colectomy in ulcerative colitis patients
T Molnár, K Farkas, T Nyári, Z Szepes, F Nagy, T Wittmann
J Gastrointestin Liver Dis 20 (4), 359-363, 2011
The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases
K Farkas, Z Saródi, A Bálint, I Földesi, L Tiszlavicz, M Szűcs, T Nyári, ...
Journal of Crohn's and Colitis 9 (3), 231-237, 2015
Prediction of short-and medium-term efficacy of biosimilar infliximab therapy. Do trough levels and antidrug antibody levels or clinical and biochemical markers play the more …
L Gonczi, Z Vegh, PA Golovics, M Rutka, KB Gecse, R Bor, K Farkas, ...
Journal of Crohn's and Colitis 11 (6), 697-705, 2017
The system can't perform the operation now. Try again later.
Articles 1–20